We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Croissance des activités réalisées aux laboratoires d’Évry Plan de restructuration et de réduction des coûts lié à l’arrêt des prestations pour le GCS SeqOIA en février Résilience de la...
The discontinuation of services for the SeqOIA platform mechanically led to a 20% reduction in revenues in the first half of the year. Adjusted for this base effect, growth was 6% over the...
Increase in services provided in 2023 by all sequencing platforms, excluding COVID-related activities Positive EBITDA for the third year running, despite inflation impacting reagent costs SeqOIA...
Significant reduction of COVID-19 related activities Growth of all other lines of business Cash totaling €2.9m on Dec 31st, 2023 Laboratory in Évry accredited by the College of American...
Résilience de la rentabilité malgré le contexte inflationniste Croissance des activités aux laboratoires d’Évry Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME...
Baisse de l’activité de la plateforme de séquençage en microbiologie après une forte contribution enregistrée au 1er semestre 2022 dans le cadre de la pandémie de Covid-19. Retraitée de cet...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.026 | -5.43933054393 | 0.478 | 0.48 | 0.452 | 2839 | 0.47357484 | DE |
4 | -0.063 | -12.2330097087 | 0.515 | 0.57 | 0.452 | 3116 | 0.50061513 | DE |
12 | -0.123 | -21.3913043478 | 0.575 | 0.67 | 0.452 | 4778 | 0.52509924 | DE |
26 | -0.188 | -29.375 | 0.64 | 0.84 | 0.452 | 4674 | 0.60043395 | DE |
52 | -0.568 | -55.6862745098 | 1.02 | 1.05 | 0.452 | 4575 | 0.68723595 | DE |
156 | -0.628 | -58.1481481481 | 1.08 | 2.04 | 0.452 | 5598 | 1.19339337 | DE |
260 | -0.538 | -54.3434343434 | 0.99 | 2.67 | 0.452 | 32784 | 1.69938282 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions